PR Newswire Clinical TrialsOriginal article
Amygdala Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for ANS-858
RegulatoryapprovedANS-858Positive
AI Analysis
Summary
Amygdala Neurosciences announced FDA clearance of its IND application for ANS-858, an ALDH2 inhibitor being developed to reduce pathological craving in alcohol and substance use disorders, with additional therapeutic opportunities in binge eating, obesity, and oncology.
Outcome Details
FDA clearance of Investigational New Drug (IND) application
Importance:6/10
Sentiment:
0.70
IND clearancesubstance use disorderALDH2 inhibitorrare disease
Read the original article
Published by PR Newswire Clinical Trials on August 18, 2026 7:00 AM